Search clinical trials for: LX4211

Total 29 results

Lexicon Pharmaceuticals

Completed

Efficacy, Safety, and PK of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1)

Diabetes | Diabetic Peripheral Neuropathy

United States
Lexicon Pharmaceuticals

Completed

Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia (RELIEF-PHN1)

Postherpetic Neuralgia

United States, Czechia, Poland
Lux Biosciences, Inc.

Completed

Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis

Noninfectious Uveitis

France, United States, Italy, Germany, Canada, United Kingdom, Czech Republic, Austria, Brazil
Lux Biosciences, Inc.

Completed

A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis (LUMINATE)

Panuveitis | Uveitis, Posterior | Uveitis, Intermediate

United States, United Kingdom, Canada, Germany, Austria, France, India
Lexicon Pharmaceuticals

Recruiting

A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) (PROGRESS)

Diabetic Peripheral Neuropathic Pain

United States
Lexicon Pharmaceuticals

Completed

Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects

Healthy

United States
Lux Biosciences, Inc.

Completed

A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis (LUMINATE)

Uveitis, Anterior | Panuveitis

United Kingdom, Canada, United States, Germany, Austria, France, India
Lux Biosciences, Inc.

Completed

A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis (LUMINATE)

Panuveitis | Uveitis, Posterior | Uveitis, Intermediate

United States, United Kingdom, Canada, Germany, Austria, France, India
CohBar, Inc.

Completed

A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease

United States
Lexicon Pharmaceuticals

Completed

Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

Type 2 Diabetes Mellitus

United States
Seagen Inc.
Gynecologic Oncology Group; European Network of Gynaecological Oncological... and other collaborators

Completed

A Trial of Tisotumab Vedotin in Cervical Cancer

Cervical Cancer

Belgium, Spain, United States, Denmark, Italy, Germany, Czechia, Sweden
Lexicon Pharmaceuticals

Completed

Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Lexicon Pharmaceuticals

Completed

Study of LX4211 in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Lexicon Pharmaceuticals

Completed

Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects

Healthy

United States
Lexicon Pharmaceuticals

Completed

Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

Type 2 Diabetes Mellitus | Renal Impairment

United States
Lexicon Pharmaceuticals

Completed

Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects

Healthy Subjects

United States
Lexicon Pharmaceuticals

Completed

DDI Study With Multiple-dose LX4211 and Single Dose Digoxin

Healthy

United States
Lexicon Pharmaceuticals

Completed

DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin

Healthy

United States
Joyce O'Shaughnessy
Takeda

Completed

TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer

United States
Lux Biosciences, Inc.

Terminated

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

Corneal Diseases | Cornea Transplant

United States, Germany
Lux Biosciences, Inc.

Terminated

Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

Corneal Transplantation | Corneal Graft Rejection

United States, Germany
Lexicon Pharmaceuticals

Completed

Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets

Healthy

United States
Lexicon Pharmaceuticals
Sanofi

Completed

A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone (inTandem3)

Type 1 Diabetes Mellitus (T1DM) | High Level of Sugar (Glucose) in the Blood

United States, Australia, Spain, Belgium, Argentina, Bulgaria, Canada, Colombia, Czechia, France, Germany, Hungary, Israel, Italy, New Zealand, Poland, Slovakia, South Africa, United Kingdom
Lexicon Pharmaceuticals

Completed

Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects (AME)

Healthy

United States
Lexicon Pharmaceuticals
Sanofi

Completed

Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy (inTandem1)

Type 1 Diabetes Mellitus

United States, Canada
Lexicon Pharmaceuticals
Sanofi; Juvenile Diabetes Research Foundation

Completed

Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C

Type 1 Diabetes Mellitus

United States
Lexicon Pharmaceuticals

Completed

A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
Lexicon Pharmaceuticals

Completed

A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics

Type 2 Diabetes Mellitus

United States

3

Subscribe